Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Concomitant Fluzone High-Dose Quadrivalent and Moderna COVID-19 Vaccine
NCT04969276Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2021
- Primary completion
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Efluelda, elasomeran in influenza, coronavirus disease 2019 (COVID-19), sponsored by Sanofi. Started Jul 2021; status: completed.
02
Drugs
Eflueldaelasomeran
03
Conditions
influenzacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04969276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969276.